Accelerating the development of life-preserving therapies for patients at high-risk of cardiovascular diseases

About Anthos

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.

Anthos is a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), one of the worlds’ leading pharmaceutical companies. The company is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular disease.

About Abelacimab

Anthos’ priority R&D program is abelacimab, a potent monoclonal antibody directed at novel targets within the coagulation cascade: Factor XI and XIa. Early research data indicate that abelacimab has the potential to provide effective protection from thromboembolic events whilst reducing the hazard of a clinically significant bleeding risk – presenting an entirely new paradigm within the anticoagulation field.

Abelacimab Icon

A major unmet need

More than 1 in 4 people worldwide die from thromboembolic events1,2 – a death toll due in part to the widespread underutilization, under-dosing and early discontinuation of anticoagulation.3,4 A strong deterrent to optimal prescribing is fear of major bleeds. The risk of bleeding – especially in frail, elderly patients not represented in clinical trials – stems from the fact that all conventional anticoagulants, including DOACs, impact physiological hemostasis as well as pathological thrombosis.

Abelacimab Icon

The need for a paradigm shift

New scientific understanding shows that taking aim at an entirely new target, Factor XI, could enable pharmacological ‘uncoupling’ of the physiological hemostasis and pathological thrombosis pathways, potentially fulfilling the ultimate ambition of vital protection from thromboembolic events whilst reducing the hazard of a clinically significant bleeding risk.

Abelacimab Icon

Abelacimab: a unique Factor XI/XIa inhibitor

Abelacimab is a potent biologic molecule designed to achieve profound Factor XI suppression through dual activity against Factor XI and its activated counterpart, Factor XIa. Created for the heterogeneous real world and for use in different healthcare settings, abelacimab has the potential to address a major unmet need.

1. Wendelboe AM, Raskob GE. Circ Res 2016; 118, 1340–1347. 2. Editorial. Lancet Haematology 2015, Vol 2, e393. 3. Piccini JP et al. Circulation. 2019;139:1497–1506. 4. Alamneh EA et al. Am J Cardiovasc Drugs 2016; 16:183–200.

Management Team

Alex Yi

Alex Yi Photo

Dan Bloomfield

Dan Bloomfield Photo

Debra Freedholm

Debra Freedholm Photo

Janeen Salter

Janeen Salter Photo

Jessica Patrick Seabrook

Jessica Patrick Seabrook Photo

John Glasspool

John Glasspool Photo

Jonathan Freeman, Ph.D.

Jonathan Freeman Photo

Lynn Mallett

Lynn Mallett Photo

Nik Mehta

Nik Mehta Photo

Yasser Khder

Yasser Khder Photo

Charles Hsu

Charles Hsu Photo

Board of Directors

Nicholas Galakatos, Ph.D.

Nick Galakatos Photo

Paris Panayiotopoulos

Paris Panayiotopoulos Photo

Scott Beardsley

Scott Beardsley Photo

Ari Brettman, M.D.

Ari Brettman Photo

Shaun Coughlin, M.D., Ph.D.

Shaun Coughlin Photo

Richard Pasternak, M.D.

Richard Pasternak Photo

Greg Norden

Greg Norden Photo

Our Investors

Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors. Investments are of sufficient scale to allow companies or products to reach meaningful value inflection points and are made in conjunction with hands-on operational leadership. In launching this new platform, Blackstone acquired Clarus, a leading global life-sciences firm.



Anthos Therapeutics is Developing a Hemostasis-Sparing Anticoagulant to Reduce the Hazard of Bleeding

Read More

Anthos Therapeutics dubbed one of the fiercest biotech companies in the world

Read More

Blackstone Life Sciences and Novartis Create Anthos Therapeutics to Develop Innovative Targeted Medicines for Cardiovascular Disease

Read More


Koch AW, Schiering N, Melkko S, et al. MAA868—a novel FXI antibody with a unique binding mode—shows durable effects on markers of anticoagulation in humans. Blood 2019; blood-2018-10-880849.

Accessed February 21, 2019